KYMR Stock Forecast: Kymera Therapeutics, Inc. Price Predictions for 2026-2027
The 24 Wall Street analysts covering Kymera Therapeutics, Inc. hold a median 12-month price target of $144 — +25.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 65 of 100 as at 21 Nov 2026 — in the upper half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Kymera Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (97): The shares have been drifting up relative to others.
Accruals (31): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
KYMR stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on KYMR, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +25.0% from it.
Of the 20 most recent actions, 14 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 2 Nov 2026 | Barclays | Maintains | Overweight | $139 → $170 |
| 30 Oct 2026 | RBC Capital | Maintains | Sector Perform | $112 → $116 |
| 30 Oct 2026 | Truist Securities | Reiterates | Buy | $136 → $150 |
| 29 Oct 2026 | BTIG | Maintains | Buy | $134 → $139 |
| 27 Oct 2026 | Morgan Stanley | Maintains | Overweight | $135 → $146 |
| 9 Oct 2026 | Raymond James | Initiates | Outperform | $140 |
| 5 Oct 2026 | Citigroup | Maintains | Buy | $135 → $150 |
| 22 Sept 2026 | Stifel | Maintains | Buy | $132 → $152 |
| 14 Sept 2026 | B of A Securities | Maintains | Buy | $123 → $144 |
| 10 Sept 2026 | Wolfe Research | Upgrade | Outperform | — |
| 31 Aug 2026 | Guggenheim | Maintains | Buy | $135 → $170 |
| 27 Aug 2026 | Wells Fargo | Maintains | Overweight | $116 → $151 |
| 6 Aug 2026 | Barclays | Maintains | Overweight | $133 → $139 |
| 30 July 2026 | Deutsche Bank | Initiates | Hold | $120 |
| 28 July 2026 | Guggenheim | Maintains | Buy | $125 → $135 |
| 16 July 2026 | Mizuho | Maintains | Outperform | $120 → $140 |
| 13 July 2026 | RBC Capital | Downgrade | Sector Perform | $106 → $115 |
| 30 June 2026 | B of A Securities | Maintains | Buy | — |
| 29 June 2026 | B. Riley Securities | Maintains | Buy | — |
| 29 June 2026 | Truist Securities | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for KYMR.
This page is one stock. Monday covers all of them.
KYMR appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
KYMR vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Kymera Therapeutics, Inc. returned +78.3% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
KYMR analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 97.6×
- Price / book
- 6.2×
- EV / EBITDA
- —
Cheaper than 3% of US stocks
Cheaper than 14% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −27.3%
- Return on assets
- −17.6%
- Dividend yield
- —
Higher than 29% of US stocks
Higher than 21% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Kymera Therapeutics, Inc. has a market value of $10.2B and an enterprise value of $9.3B.
Revenue in the twelve months to 30 June 2026: $105.0M. The latest quarter grew 466.4% year on year.
Net income over the same four quarters: −$299.6M, a −285.3% net margin.
Diluted earnings per share, trailing twelve months: −$3.24.
Free cash flow in the twelve months to 30 June 2026: −$238.0M.
Kymera Therapeutics, Inc. employs 285 people — $368K of revenue per employee.
Data provided by Twelve Data
KYMR and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at KYMR’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Kymera Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about KYMR
What is the KYMR stock price forecast for 2026-2027?
The 24 Wall Street analysts covering Kymera Therapeutics, Inc. have a median 12-month price target of $144, with estimates ranging from $116 to $180. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is KYMR stock a buy right now?
Of the 24 analysts covering Kymera Therapeutics, Inc., 22 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Kymera Therapeutics, Inc. 65 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank KYMR?
As at 21 Nov 2026, Kymera Therapeutics, Inc. ranks 65 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Momentum (97 of 100).
Will KYMR stock go up?
No one can know that. What the data says: the median 12-month target from 24 analysts implies +25.0% from the last close, and Ticker Nerd's factor model ranks Kymera Therapeutics, Inc. 65 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the KYMR stock forecast for 2030?
No analyst covering Kymera Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for KYMR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $116 to $180 over the next 12 months.
How has KYMR stock performed over the past year?
Kymera Therapeutics, Inc. returned +78.3% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Kymera Therapeutics, Inc. do?
Kymera Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule medicines that use targeted protein degradation to address disease-causing proteins. The company’s work centers on harnessing the body’s natural protein recycling systems to create oral therapies designed for conditions that are difficult to treat with conventional approaches.
About Kymera Therapeutics, Inc.
Kymera Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule medicines that use targeted protein degradation to address disease-causing proteins. The company’s work centers on harnessing the body’s natural protein recycling systems to create oral therapies designed for conditions that are difficult to treat with conventional approaches. Its current programs span immunology, inflammation, and oncology, with research aimed at diseases such as atopic dermatitis, hidradenitis suppurativa, autoimmune disorders, and certain cancers. Kymera Therapeutics Inc. operates through a differentiated drug-discovery platform that supports both internal pipeline development and strategic research collaborations. Headquartered in Watertown, Massachusetts, the company plays a specialized role in the biotechnology market by advancing novel treatment approaches for serious diseases.
CEO Dr. Nello Mainolfi M.D., Ph.D. · 285 employees · United States · https://www.kymeratx.com